ArticleCanadian journal of gastroenterology & hepatology2026
Short- and Long-Term Healthcare Costs Attributable to Hepatitis B Among Newcomers to Ontario, Canada: A Matched Cohort Study.
Article in Canadian journal of gastroenterology & hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Short- and Long-Term Healthcare Costs Attributable to Hepatitis B Among Newcomers to Ontario, Canada: A Matched Cohort Study.Canadian journal of gastroenterology & hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHealthcare expenditures across the clinical trajectory of hepatitis B virus (HBV) infection are inadequately characterized, particularly among immigrants. Our aim is to quantify HBV-attributable short- and long-term costs among a population of newcomers to the province of Ontario.
methodsWe performed a cost-of-illness study with an incidence-based, matched cohort design, employing linked population-based laboratory and health administrative data, and permanent residence data from Immigration, Refugees and Citizenship Canada (IRCC). We identified newcomers diagnosed with HBV between January 1, 2004, and December 31, 2018, and dichotomized the study cohort into individuals with or without liver complications before diagnosis. We used propensity score matching and phase-of-care costing to quantify monthly attributable costs for each of six HBV phases and longitudinal costs for one, five, and ten years following diagnosis. Costs were quantified in 2021 Canadian dollars.
resultsAmong n = 30,677 newcomers with HBV, 2.7 percent had complications before diagnosis. Mean monthly phase costs were higher for individuals with complications before diagnosis relative to those without for prediagnosis care ($439, 95% CI: $250-$645 vs. $22, 95% CI: $12-$34), initial care for HBV ($1545, 95% CI: $1196-$1945 vs. $331, 95% CI: $299-$369), continuing care for HBV ($537, 95% CI: $314-$760 vs. $73, 95% CI: $55-$92), and final care ($7271, 95% CI: $3749-$10,747 vs. $3430, 95% CI: $1813-$5061).
conclusionsFindings emphasize the dynamic nature of HBV-attributable costs and highlight the importance of care following diagnosis and complication onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.